Registration for a live webinar on 'The role of T cells in COVID from asymptomatic to severe outcomes' is now open.
See webinar details- View the Talks
-
64 min
1. Current trends in antiviral drug development- Prof. Dr. Erik De Clercq
-
76 min
2. Antivirals versus vaccines- Prof. Albert D.M.E. Osterhaus
-
58 min
3. Prospects of anti-HIV therapy and prophylaxis- Prof. Dr. Erik De Clercq
-
38 min
-
9 min
5. The path towards a cure for chronic hepatitis B- Prof. Fabien Zoulim
-
70 min
6. Influenza antivirals: update- Prof. Frederick G. Hayden
-
35 min
-
45 min
8. Nucleoside phosphonates as inhibitors of HIV- Dr. Tomas Cihlar
-
59 min
9. HIV-1 integrase inhibitors- Prof. Martin Markowitz
-
52 min
-
32 min
11. HIV entry inhibitors- Prof. José Esté
-
39 min
12. Antiviral therapy of orthopoxvirus infection- Prof. Earl R. Kern
- Prof. Mark N. Prichard
-
25 min
13. Herpes simplex virus antiviral chemotherapy- Dr. Hugh J. Field
-
30 min
14. Cyclophilin inhibitors for HCV- Prof. Robert Flisiak
- Archived Lectures *These may not cover the latest advances in the field
-
50 min
-
62 min
Printable Handouts
Navigable Slide Index
- Introduction
- Orthopoxviruses
- Why are antiviral therapies required?
- Replication of orthopoxviruses
- Properties of an ideal drug
- Inhibitors of orthopoxvirus replication
- Potential candidates
- Animal models for anti-orthopoxvirus drugs
- Efficacy against vaccinia virus and cowpox virus
- Cidofovir (CDV)
- Mechanism of action of CDV
- Interval of CDV treatment against cowpox virus
- Single dose CDV affects mortality of cowpox virus
- Single dose CDV affects mortality of vaccinia virus
- Parenteral or topical CDV affect virus titers
- Vaccinia virus (VV) titers after topical/i.p. CDV
- CMX001
- Phosphonate nucleotides and alkoxyalkyl analogs
- Effects of HDP-CDV/ODE-CDV on mortality on VV
- Effects of oral treatment with CMX001 on VV
- Effect of daily oral HDP-CDV/ODE-CDV - Cowpox
- Effect of daily oral HDP-CDV/ODE-CDV - Vaccinia
- Effect of oral CMX001 on ectromelia virus (ECTV)
- Efficacy of oral CMX001 in rabbitpox virus
- CMX001 and CDV pharmacokinetic studies
- ST-246 (tecovirimat)
- Inhibition of extracellular virus formation by ST-246
- Delayed ST-246 treatment - Cowpox virus
- Once-daily oral ST-246 treatment - Cowpox virus
- Once-daily oral ST-246 treatment - Vaccinia virus
- Delayed treatment with ST-246 - ECTV
- Twice-daily treatment with ST-246 - ECTV
- Once-daily treatment with ST-246 - ECTV
- Summary of ST-246 efficacy
- 4'-thioIDU
- Efficacy and toxicity of 4'-thioIDU
- Activity of 4'-thioIDU - WT and resistant VV
- Role of TK in 4'-thioIDU activity - Cowpox virus
- Mutant resistant to 4'-thioIDU
- Selection of a 4'-thioIDU resistant mutant
- Viral TK homologs
- Crystal structure of VV TK
- TK active sites in human and vaccinia
- Kinetic parameters for TK substrates
- 4'-thioIDU incorporation into viral DNA
- Oral treatment with 4'-thioIDU in CV
- Oral treatment with 4'-thioIDU in VV
- Combination chemotherapy
- CMX001 and ST-246 against CV and VV
- Oral CMX001 and ST-246 treatment of CV
- 4'-thioIDU potentiates CMX001 and ST-246 activity
- Clinical development
- Summary
- Acknowledgments
Topics Covered
- Orthopoxviruses that infect humans
- Effective antiviral therapies
- Development of CMX001
- Development of ST-246
- Mechanism of action of drugs
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kern, E.R. and Prichard, M.N. (2011, August 31). Antiviral therapy of orthopoxvirus infection [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 26, 2024, from https://hstalks.com/bs/2079/.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Earl R. Kern has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
- Prof. Mark N. Prichard has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Antiviral therapy of orthopoxvirus infection
Published on August 31, 2011
39 min
